WO2009118411A2 - 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them - Google Patents
3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them Download PDFInfo
- Publication number
- WO2009118411A2 WO2009118411A2 PCT/EP2009/053668 EP2009053668W WO2009118411A2 WO 2009118411 A2 WO2009118411 A2 WO 2009118411A2 EP 2009053668 W EP2009053668 W EP 2009053668W WO 2009118411 A2 WO2009118411 A2 WO 2009118411A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- alkyl
- group
- give
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 230000008569 process Effects 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- KRRWBFJXTNMYOZ-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one Chemical class C1=CC=C2N3CCNC(=O)C3=CC2=C1 KRRWBFJXTNMYOZ-UHFFFAOYSA-N 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 296
- 150000003839 salts Chemical class 0.000 claims abstract description 52
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 25
- 108060006633 protein kinase Proteins 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000002062 proliferating effect Effects 0.000 claims abstract description 5
- 238000011161 development Methods 0.000 claims abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 4
- 208000030507 AIDS Diseases 0.000 claims abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 3
- 208000036142 Viral infection Diseases 0.000 claims abstract description 3
- 230000001363 autoimmune Effects 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 230000009385 viral infection Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 70
- -1 Ci-C6 alkyl Chemical group 0.000 claims description 55
- 229920005989 resin Polymers 0.000 claims description 55
- 239000011347 resin Substances 0.000 claims description 55
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 22
- 108091000080 Phosphotransferase Proteins 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 102000020233 phosphotransferase Human genes 0.000 claims description 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 150000001412 amines Chemical class 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 230000002378 acidificating effect Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 229910052701 rubidium Inorganic materials 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 150000001299 aldehydes Chemical class 0.000 claims description 7
- 230000009435 amidation Effects 0.000 claims description 7
- 238000007112 amidation reaction Methods 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 claims description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 235000011150 stannous chloride Nutrition 0.000 claims description 5
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 238000005809 transesterification reaction Methods 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 238000007098 aminolysis reaction Methods 0.000 claims description 3
- 238000011319 anticancer therapy Methods 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 238000009104 chemotherapy regimen Methods 0.000 claims description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 201000004931 neurofibromatosis Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000015768 polyposis Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 229910014033 C-OH Inorganic materials 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 229910021554 Chromium(II) chloride Inorganic materials 0.000 claims description 2
- 229910014570 C—OH Inorganic materials 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001266 acyl halides Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- XBWRJSSJWDOUSJ-UHFFFAOYSA-L chromium(ii) chloride Chemical compound Cl[Cr]Cl XBWRJSSJWDOUSJ-UHFFFAOYSA-L 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- AMVCMHXBGWPOTF-UHFFFAOYSA-M sulfanide;tetrabutylazanium Chemical compound [SH-].CCCC[N+](CCCC)(CCCC)CCCC AMVCMHXBGWPOTF-UHFFFAOYSA-M 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 103
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 94
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000725 suspension Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 14
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 0 *C(CC(CN*(c1cc2c3)=O)[n]1c2ccc3NS(=O)=O)=O Chemical compound *C(CC(CN*(c1cc2c3)=O)[n]1c2ccc3NS(=O)=O)=O 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- GSMHQIGSTGUVLQ-UHFFFAOYSA-N n-(2,2-dimethoxyethyl)-5-nitro-1h-indole-2-carboxamide Chemical compound [O-][N+](=O)C1=CC=C2NC(C(=O)NCC(OC)OC)=CC2=C1 GSMHQIGSTGUVLQ-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000001311 chemical methods and process Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 101100166531 Drosophila melanogaster CycC gene Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000002942 anti-growth Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100381333 Arabidopsis thaliana AUR2 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 108091054872 CK2 family Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101100273645 Gallus gallus CCNA2 gene Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical group NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- LHFOJSCXLFKDIR-UHFFFAOYSA-N [O-][N+](c(cc1)cc2c1[nH]c(C(O)=O)c2)=O Chemical compound [O-][N+](c(cc1)cc2c1[nH]c(C(O)=O)c2)=O LHFOJSCXLFKDIR-UHFFFAOYSA-N 0.000 description 1
- KGKMFNAHCZCXNR-UHFFFAOYSA-N [O-][N+](c1ccc2[n](C(CC(O)=O)CNC3=O)c3cc2c1)=O Chemical compound [O-][N+](c1ccc2[n](C(CC(O)=O)CNC3=O)c3cc2c1)=O KGKMFNAHCZCXNR-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005281 alkyl ureido group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- DVFJMQCNICEPAI-UHFFFAOYSA-N ethyl 5-nitro-1h-indole-2-carboxylate Chemical compound [O-][N+](=O)C1=CC=C2NC(C(=O)OCC)=CC2=C1 DVFJMQCNICEPAI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000008214 highly purified water Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- DTFDUIVYVHCCQG-UHFFFAOYSA-N n-benzyl-4-(4-formyl-3-methoxyphenoxy)butanamide Chemical compound C1=C(C=O)C(OC)=CC(OCCCC(=O)NCC=2C=CC=CC=2)=C1 DTFDUIVYVHCCQG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compounds which are 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one derivatives or pharmaceutically acceptable salts thereof,their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment ofdiseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.
Description
TITLE OF THE INVENTION
3,4-DIHYDRO-2H-PYRAZINO[l,2-A]INDOL-l-ONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM.
The present invention relates to certain 8-amino derivatives of 3,4-dihydro-2H- pyrazino[l,2-a]indol-l-one compounds, which modulate the activity of protein kinases. The compounds of this invention are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also relates to methods for preparing these compounds, combinatorial libraries thereof, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. The malfunctioning of protein kinases (PKs) is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers code for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders. For a general reference to PKs malfunctioning or disregulation see, for instance, Current Opinion in Chemical Biology 1999, 3, 459 - 465 and Carcinogenesis 2008, 29, 1087- 191.
3,4-Dihydro-2H-pyrazino[l,2-a]indol-l-one derivatives for the treatment of disorders of the central nervous system and obesity are disclosed in WO 2002/010169 and WO 2002/072584, all in the name of F.Hoffmann-La Roche A.-G. and Vernalis Research (Limited).
8-Oxy derivatives of 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one for the treatment of obesity are disclosed in WO2007/065820 in the name of F.Hoffmann-La Roche A.-G.
7-Carmaboyl-derivatives of 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one for the treatment of cytokine mediated diseases such as rheumatoid arthritis, inflammatory bowel disease and Alzheimer's disease are disclosed in US200627453, in the name of Boehringer Ingelheim Pharmaceuticals, Inc., USA. The present inventors have now discovered that the new compounds of formula (I), described below, are kinase inhibitors and are thus useful in therapy as antitumor agents.
Accordingly, a first object of the present invention is to provide a 8-amino-3,4-dihydro- 2H-pyrazino[l,2-a]indol-l-one compound represented by formula (I):
R is selected from the group consisting of -Ra, -CORa, -CONRaR , -SO2Ra and -COORa, and Rl is a group -NRcRd or -ORC, wherein Ra,Rb,Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched Ci-C6 alkyl, C2- C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl Ci-C6 alkyl, heterocyclyl or heterocyclyl Ci-C6 alkyl, aryl or aryl Ci-C6 alkyl, heteroaryl or heteroaryl Ci-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof. The present invention also provides methods of synthesizing the substituted 8-amino- 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one compounds, represented by formula (I), prepared through a process consisting of standard synthetic transformations.
The present invention also provides a method for treating diseases caused by and/or associated with dysregulated protein kinase activity, particularly PLK family, ABL, AKTl, ALK, AURl, AUR2, BRK, CDC7/DBF4, CDK2/CYCA, CHKl, CK2, EE2FK, EGFRl, ERK2, FAK, FGFRl, FLT3, GSK3beta, IGFRl, IKK2, IR, JAK2, JAK3, KIT, LCK, MAPKAPK2, MET, MPSl, NEK6, NIMl, P38alpha, PAK4, PDGFR, PDKl, PERK, PIMl, PKAalpha, PKCbeta, PLKl, RET, B-RAF, STLK2, SULUl, TRKA, VEGFR2, VEGFR3, ZAP70.
A preferred method of the present invention is to treat a disease caused by and/or associated with dysregulated protein kinase activity selected from the group consisting of cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders. Another preferred method of the present invention is to treat specific types of cancer including but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including mesothelioma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.
Another preferred method of the present invention is to treat specific cellular proliferation disorders such as, for example, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
In addition, the method of the present invention also provides tumor angiogenesis and metastasis inhibition, as well as treatment of organ transplant rejection and host versus graft disease.
In a further preferred embodiment, the method of the present invention further comprises subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent. Moreover the invention provides an in vitro method for inhibiting protein kinase activity which comprises contacting the said protein kinase with an effective amount of a compound of formula (I).
The present invention also provides a pharmaceutical composition comprising one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, carrier or diluent. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) in combination with known cytostatic or cytotoxic agents, antibiotic-type agents, DNA damaging or intercalating agents, platin-based agents, alkylating agents, antimetabolite agents, hormonal agents, antihormonal agents such as antiestrogens, antiandrogens and aromatase inhibitors, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, tyrosine kinase inhibitors, other kinase inhibitors, anti- growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, inhibitors of kinesins, therapeutic monoclonal antibodies, inhibitors of mTOR, histone deacetylase inhibitors, inhibitors of hypoxic response and the like.
Additionally, the invention provides a product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, or pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy. In yet another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament. Moreover the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, in the manufacture of a medicament for treating diseases caused by and/or associated with an altered protein kinase activity.
Finally, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method for treating diseases caused by and/or associated with an altered protein kinase activity. Unless otherwise specified, when referring to the compounds of formula (I) per se as well as to any pharmaceutical composition thereof or to any therapeutic method of treatment comprising them, the present invention includes all the solvates, hydrates, complexes, metabolites, prodrugs, carriers, N-oxides and pharmaceutically acceptable salts of the compounds of this invention. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
"Hydrate" is a solvate wherein the solvent molecule is H2O.
A "metabolite" of a compound of formula (I) is any compound into which this same compound of formula (I) is converted in vivo, for instance upon administration to a mammal in need thereof. Typically, without however representing a limiting example, upon administration of a compound of formula (I), this same derivative may be converted into a variety of compounds, for instance including more soluble derivatives like hydroxylated derivatives, which are easily excreted. Hence, depending upon the metabolic pathway thus occurring, any of these hydroxylated derivatives may be regarded as a metabolite of the compounds of formula (I). The term "prodrug", as employed herein, denotes a compound that is a drug precursor, which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of formula (I) or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) Volume 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
All forms of chiral isomers or other forms of isomers including enantiomers and diastereomers, are intended to be covered herein. Compounds containing a chiral center may be used as a racemic mixture or as an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form. In the present description, unless otherwise indicated, with the term "straight or branched Ci-C6 alkyl" we intend any group such as, for instance, methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like. With the term "straight or branched C2-C6 alkenyl" or "straight or branched C2-C6 alkynyl" we intend any of the unsaturated alkenyl or alkynyl groups with from 2 to 6 carbon atoms for instance including vinyl, allyl, 1-propenyl, isopropenyl, 1-, 2- or 3- butenyl, pentenyl, hexenyl, ethynyl, 1- or 2-propynyl, butynyl, pentynyl, hexynyl, and the like.
With the term "Cs-C6 cycloalkyl" we intend, unless otherwise specified, 3- to 6- membered all-carbon monocyclic ring, which may contain one or more double bonds but does not have a completely conjugated π-electron system. Examples of cycloalkyl groups, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene and cyclohexadiene.
With the term "heterocyclyl" we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur. Non limiting examples of heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3- dioxolane, piperidine, piperazine, morpholine and the like.
With the term "aryl" we intend a mono-, bi- or poly-carbocyclic hydrocarbon with from 1 to 4 ring systems, optionally further fused or linked to each other by single bonds, wherein at least one of the carbocyclic rings is "aromatic", wherein the term "aromatic" refers to completely conjugated π-electron bond system. Non limiting examples of such aryl groups are phenyl, α- or β-naphthyl or biphenyl groups.
With the term "heteroaryl" we intend aromatic heterocyclic rings, typically 5- to 7- membered heterocycles with from 1 to 3 heteroatoms selected among N, O or S; the heteroaryl ring can be optionally further fused or linked to aromatic and non-aromatic carbocyclic and heterocyclic rings. Not limiting examples of such heteroaryl groups are, for instance, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, phenyl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindolinyl, benzoimidazolyl, quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1 -phenyl- 1, 2, 3-triazo IyI, 2,3-dihydroindolyl, 2,3- dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl; benzopyranyl, 2,3- dihydrobenzoxazinyl, 2,3-dihydroquinoxalinyl and the like.
According to the meanings provided to Ra, Rb, Rc and Rd , any of the above groups may be further optionally substituted in any of their free positions by one or more groups, for instance 1 to 6 groups, selected from: halogen, nitro, oxo groups (=0), carboxy, cyano, Ci-C6 alkyl, polyfluorinated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl; amino groups and derivatives thereof such as, for instance, alkylamino, dialkylamino, arylamino, diarylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as, for instance, formylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as, for instance, alkoxy, polyfluorinated alkoxy, aryloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy or alkylideneaminoxy; carbonyl groups and derivatives thereof such as, for instance, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as, for instance, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, arylsulfonyloxy, amino sulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl.
In their turn, whenever appropriate, each of the above substituents may be further substituted by one or more of the aforementioned groups. In the present description, unless otherwise specified, with the term "cyano" we intend a -CN residue.
With the term "nitro" we intend a -NO2 group.
With the term" halogen" we intend a fluorine, chlorine, bromine or iodine atom.
With the term "polyfluorinated alkyl or alkoxy" we intend a straight or branched Ci-C6 alkyl or alkoxy group as above defined, wherein more than one hydrogen atom is replaced by fluorine atoms such as, for instance, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethyl, 2,2,2-trifluoroethoxy, 1 ,2-difluoroethyl, 1,1,1,3,3,3- hexafluoropropyl-2-yl, and the like.
From all of the above, it is clear to the skilled man that any group which name has been identified as a composite name such as, for instance, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, alkoxy, alkylthio, aryloxy, arylalkyloxy, alkylcarbonyloxy and the like, has to be intended as conventionally construed from the parts to which it derives. So far, as an example, the terms heterocyclyl-alkyl and cycloalkyl-alkyl stand for a straight or branched alkyl group being further substituted by a heterocyclic or cycloalkyl group, respectively, as above defined.
The term "pharmaceutically acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, trifluoroacetic, propionic, succinic, glycolic, gluconic, lactic, malic, fumaric, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p- hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compounds of the present invention, for instance by reacting them with the appropriate acid or base.
A preferred class of compounds of formula (I) are the compounds wherein: Rl is a group -NRcRd and Rc and Rd are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of Rc or Rd is a straight or branched Ci-C6 alkyl or C2-C6 alkenyl group or it is an optionally substituted aryl or arylalkyl group. Another preferred class of compounds of formula (I) are the compounds wherein :
R is a group Ra wherein Ra is hydrogen, or is a group -SO2Ra wherein Ra is straight or branched Ci-C6 alkyl or optionally substituted aryl or arylalkyl.
A further preferred class of compounds of formula (I) are the compounds wherein:
R is a group -CORa wherein Ra is a straight or branched Ci-C6 alkyl, cycloalkyl or optionally substituted aryl or arylalkyl group.
A more preferred class of compounds of formula (I) are the compounds wherein:
R is a group -CONRaRb wherein one of Ra and Rb are hydrogen and the other is straight or branched Ci-C6 alkyl, optionally substituted aryl or arylalkyl group.
For a reference to any specific compound of formula (I) of the invention, optionally in the form of pharmaceutically acceptable salts, see the experimental section. The intermediate compound of formula (VII):
wherein Rl is as defined above, is novel and hence represents a further object of the invention. The present invention also provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the process comprises: a) hydro lysing under basic or acidic conditions the compound of formula (II):
with 2,2-dimethoxy-ethylamine, after activation of the carboxyl group; c) deprotecting under acidic conditions the resultant compound of formula (IV):
wherein AIk is Ci-C6 alkyl and Rc is Ci-C6 alkyl; optionally converting the resultant compound of formula (VII):
wherein Rl represents ORcand Rcis Ci-C6 alkyl, into another compound of formula (VII) by replacing the -ORC group with a different group among those represented by Rl;
e) reducing said compound of formula (VII) to give a compound of formula (I) or a salt thereof:
wherein Rl is ORC and Rc is Ci-C6 alkyl; optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by derivatising the amino moiety, and/or by replacing the group -ORC with a different group among those represented by Rl, and/or into a pharmaceutically acceptable salt if desired.
The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) prepared in steps from a) to e) described above, is converted into another compound of formula (I) by derivatising the amino moiety , said derivatization being carried out by one or more of the following reactions: f) reacting a compound of formula (I) wherein R is hydrogen and Rl is -ORC and Rc is Ci-C6 alkyl, according to any one of the alternative steps: f.l) with an acid or an acyl halide of formula (VIII):
RaCOZ (VIII) wherein Ra is as defined above and Z is a halogen or a group -OH, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.2) with an isocyanate of formula (IX):
RaNCO (IX) wherein Ra is as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.3) with a sulphonyl halide of formula (X):
RaSO2Z' (X) wherein Ra is as defined above and Z' is a halogen, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.4) with a halogen carbonate of formula (XI):
RaOCOZ' (XI) wherein Ra and Z' are as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or
f.5) with an amine of formula (XII):
HNRaRb (XII) wherein Ra and Rb are as defined above, in presence of a suitable chloro formate, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl, and Raand Rb are as defined above; or (f.6) with a suitable aldehyde or ketone derivative of formula (XIII):
Ra-CO-Ra (XIII) wherein each of Ra, the same or different, are as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and each of Ra, the same or different, are as defined above; or
(f.7) with an halide of formula (XIV):
Ra-Z' (XIV) wherein Ra and Z' are as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by replacing the group -ORC with a different group among those represented by Rl, and/or into a pharmaceutically acceptable salt if desired.
The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (I) is converted into another compound of formula (I), said conversion is carried out by one or more of the following reactions: g.l) acid or basic hydrolysis of a compound of formula (I) wherein Rl is -ORC and Rc is Ci-C6 alkyl, to give the corresponding compound of formula (I) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt; g.2) transesterification of a compound of formula (I) wherein Rl is -ORC and Rc is Ci- C6 alkyl, by reactions with a compound of formula (XV):
RC-OH (XV) to give the corresponding compound of formula (I) wherein Rl is -ORC and Rc is a different Ci-C6 alkyl; g.3) aminolysis of a compound of formula (I) wherein Ri is -ORC and Rc is Ci-C6 alkyl, by reaction with a compound of formula (XVI):
HNRcRd (XVI) to give the corresponding compound of formula (I) wherein Rl is -NRcRd ; g.4) esterification of a compound of formula (I) wherein Rl is a group -OH or its corresponding salt, by reactions with a compound of formula (XV) as defined above, to give the corresponding compound of formula (I) wherein Rl is -ORC ;
g.5) amidation of a compound of formula (I) wherein Rl is a group -OH or its corresponding salt, by reaction with a compound of formula (XVI) as defined above, to give the corresponding compound of formula (I) wherein Rl is -NRcRd. The present invention further provides a process for the preparation of a compound of formula (I) as defined above, characterized in that the compound of formula (VII) as defined above, is converted into anothe compound of formula (VII), said conversions are carried out by one or more of the following reactions: h.l) acid or basic hydrolysis of a compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl, to give a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt; h.2) transesterification of a compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl, by reaction with a compound of formula (XV) as defined above, to give a compound of formula (VII) wherein Rl is -ORC and Rcis a different Ci-C6 alkyl; h.3) amidation of a compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl, by reaction with a compound of formula (XVI) as defined above, to give a compound of formula (VII) wherein Rl is -NRcRd ; h.4) esterification of a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt, by reaction with a compound of formula (XV) as defined above, to give a compound of formula (VII) wherein Rl is -ORC and Rc is different from hydrogen; h.5) amidation of a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, by reaction with a compound of formula (XVI) as defined above, to give a compound of formula (VII) wherein Rl is -NRcRd . From all of the above, it is clear to the skilled person that if a compound of formula (I) or (VII), prepared according to the above processes comprehensive of any variant thereof, is obtained as an admixture of isomers, their separation into the single isomers of formula (I), carried out according to conventional techniques, is still within the scope of the present invention. Likewise, the conversion of a compound of formula (I) into a pharmaceutically acceptable salt thereof or, alternatively, the conversion into the free compound (I) of a corresponding salt, according to procedures well-known in the art, is still within the scope of the invention.
When preparing the compounds of formula (I) according to any variant of the process, which are all to be intended as within the scope of the invention, optional functional groups within the starting materials, the reagents or the intermediates thereof, and which could give rise to unwanted side reactions, need to be properly protected according to conventional techniques.
The starting materials of the process object of the present invention, comprehensive of any possible variant, as well as any reactant thereof, are known compounds and if not commercially available per se may be prepared according to well-known methods. Likewise, the compounds of formula (II), (VI), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), are known or easily obtained according to known methods, for a general reference see: Smith, Michael - March's Advanced Organic Chemistry: reactions mechanisms and structure - 5th Edition, Michael B. Smith and Jerry March, John Wiley & Sons Inc., New York (NY), 2001. According to step (a) of the process, the hydrolysis of the compound of formula (II) under basic or acidic conditions can be carried out in a variety of ways, according to conventional methods for hydrolysing esters derivatives. Preferably, the reaction is carried out in the presence of aqueous lithium hydroxide, methanol and tetrahydrofuran, at a temperature ranging from room temperature to about 900C and for a time from 4 hours to one day. According to the operative conditions being employed, the compound of formula (III) could be obtained either in its acidic form or, alternatively, as a salt. According to step (b) of the process, the conversion of the compound of formula (III) into the corresponding amido derivative of formula (IV), can be carried out in a variety of ways, according to conventional methods for obtaining amido derivatives from the corresponding acids. For example the reaction may be carried out by reaction with 2,2- dimethoxy-ethylamine after activation of the carboxylic function of the compound of formula (III) by reaction with thionyl chloride, oxalyl chloride or alternatively in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDC), O-benzotriazolyl-tetramethyl- isouronium tetrafluoroborate (TBTU) or benzotriazol-1-yloxy-tripyrrolidino- phosphonium hexafluorophosphate (PyBOP). Preferably, the reaction is carried out using thionyl chloride in dioxane as solvent and the isolated acyl chloride, by volatiles removal, is reacted with 2,2-dimethoxy-ethylamine under well-known Schotten- Baumann conditions.
According to step (c) of the process, the deprotection of the di-methyl acetal of the compound of formula (IV) can be carried out in a variety of ways, according to conventional methods for acetal removal. Preferably, the reaction is carried out in the presence of a suitable solvent, for instance in acetone and water, under acidic conditions, for instance in the presence of a mineral acid, preferably hydrochloric acid. According to step (d) of the process, the reaction of the compound of formula (V) with compound of formula (VI) can be carried out in a variety of ways, according to conventional methods for Horner-Emmons reaction. Preferably, the reaction is carried out using different organic or inorganic bases such as lithium hydroxide in tetrahydrofuran and water or l,8-diazabicyclo[5.4.0]undec-7-ene in acetonitrile with the trimethyl phosphonoacetate of formula (VI).
According to step (e) of the process, the reduction of the nitro group of the compound of formula (VII) to give a compound of formula (I), can be carried out in a variety of ways, according to conventional methods for reducing nitro group to the corresponding amino derivative. Preferably the reaction is carried out in the presence of tin (II) chloride in dimethylformamide (DMF) at room temperature for a time ranging from 4 to 24 hours. According to any one of steps (f.l) to (f.7) the preparation of functionalized amino derivatives starting from the corresponding amine can be carried out in a variety of ways, according to conventional methods. Preferably, according to step (f.l), (f.3) and (f.4) of the process, the compound of formula (I) is dissolved in a suitable solvent such as dichloromethane, dimethylformamide, tetrahydrofuran, dioxane or the like, and a suitable base such as triethylamine, diisopropylethylamine or sodium carbonate is added therein. The compounds of general formula (VIII), (X) or (XI) are then added and the mixture stirred for a time of about 2 hours to about 15 hours, at a temperature ranging from about 200C to about 800C. A suitable catalyst such as dimethylamino pyridine may be optionally used.
Preferably according to step (f.2) of the process, the reaction conditions are the same as above reported for steps (f.l), (f.3) and (f.4) except that the base may not be required. The compound of general formula (IX) is then added and the mixture stirred as reported above for steps (f.l), (f.3) and (f.4).
Preferably according to step (f.5) of the process, the compound of formula (I) is reacted with an amino derivative of formula (XII) after activation by reaction with a suitable
chloroformate such as, for instance, 4-nitrophenylchloroformate. The reaction is carried out in a suitable solvent such as a halogenated hydrocarbon, preferably dichloromethane, in the presence of a base such as, for instance, diisopropylethylamine or triethylamine and by working at room temperature. Preferably according to step (f.6) of the process, the compound of formula (I) is with reacted with an aldehyde or ketone derivative of formula (XIII). It is clear to the skilled man that by employing an aldehyde derivative of formula (XIII) wherein one of the two Ra is a hydrogen atom, the corresponding derivatives wherein R is -CH2R*1 are obtained. Likewise, by employing a ketone derivative, compounds having R as -CH(Ra)Ra are obtained, wherein each Ra is, independently from each other, as set forth above but other than hydrogen. The reaction can be carried out in a variety of ways, according to conventional methods for reductive amination. Preferably, the reaction is carried out by reaction with an aldehyde or ketone derivative of formula (XIII) in a suitable solvent such as tetrahydrofuran and after a time from 2 to 12 hours by addition of a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride.
Preferably according to step (f.7) of the process, the compound of formula (I) is reacted with an aromatic iodide or bromide of formula (XIV) in the presence of a suitable catalyst, for instance a palladium catalyst like palladium acetate or Pd2(dba)3, and of a suitable ligand. See, for a general reference to the above arylation reaction and operative conditions thereof also inclusive of solvents, catalysts and ligands, J. Am. Chem. Soc, (2003), 125, 6653-55; JOC (2001), 66, 2560-2565; and JOC (2002), 67, 6479-6486. According to any one of steps (g.l) to (g.5) the conversion of a compound of formula (I) into another compound of formula (I) can be carried out in a variety of ways, according to conventional methods. Preferably according to step (g.l) of the process, the hydro lysys of a compound of formula (I) wherein Rl is -OCH3, to give the corresponding compound of formula (I) wherein Rl is -OH is carried out under acidic or basic conditions. Preferably, the reaction is carried out as described under step (a). According to the operative conditions being employed, the compound of formula (I) wherein Rl is -OH could be obtained either in its acidic form or, alternatively, as a salt.
Preferably according to step (g.2) of the process, the transesterifϊcation of a compound of formula (I) wherein Rl is -OCH3, to give the corresponding compound of formula (I) wherein Rl is -ORC and Rc is an alkyl different from methyl, is carried out by reaction
with a compound of formula (XV) in an appropriate solvent, such as the compound of formula (XV) itself or dioxane at the refluxing temperature, optionally in the presence of a suitable metal based catalysts, like dibutylin oxide or titanium alkoxides such as, for instance, titanium (IV) ethoxide, titanium (IV) isopropoxide and the like. Preferably according to step (g.3) of the process, the aminolysis of a compound of formula (I) wherein Rl is -OCH3, to give the corresponding compound of formula (I) wherein Rl is -NRcRd , is carried out in an appropriate solvent such as dioxane or dichloromethane optionally in the presence of a suitable metal based catalysts, like trimethyl aluminium. Preferably according to step (g.4) of the process, the esterifϊcation of a compound of formula (I) wherein Rl is a group -OH to give the corresponding compound of formula (I) wherein Rl is -ORC, is carried out in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3'-dimethylaminopropyl)- carbodiimide (EDC), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), in an appropriate solvent such as dichloromethane, dimethylformamide. Preferably according to step (g.5) of the process, the amidation of a compound of formula (I) wherein Rl is a group -OH to give the corresponding compound of formula (I) wherein Rl is -NRcRd can be carried out in a variety of ways, according to conventional methods for obtaining amido derivatives from the corresponding acids. Preferably, the reaction is carried out by reaction with compound of formula (XVI) after activation of the carboxylic function of the compound of formula (I) by reaction with thionyl chloride, oxalyl chloride or alternatively in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide (EDC), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), in an appropriate solvent such as dichloromethane, and/or dimethylformamide. According to any one of steps (h.l) to (h.5) the conversion of a compound of formula (VII) into another compound of formula (VII) can be carried out in a variety of ways, according to conventional methods. Preferably it is carried out as described under the steps from (g.l) to (g.5).
In addition to the above, the compounds of formula (I) may be advantageously prepared according to combinatorial chemistry techniques widely known in the art, by accomplishing the aforementioned reactions between the intermediates in a serial manner and by working under solid-phase-synthesis (SPS) conditions.
As an example, the intermediate carboxy ester derivatives of formula (VII), wherein Rl represents ORC and Rc 1S Ci-C6 alkyl, being obtained in step (d) of the above processes, can be first converted into the free carboxy acid derivative by means of hydrolysis carried out according to conventional methods, then easily supported onto a polymeric resin, for instance through the formation of a carboxamido group.
The intermediate thus supported may be subsequently reacted according to the remaining steps of the process.
The above synthetic pathway can be summarized as follows:
Any of the above reactions is carried out according to known methods, by working as formerly reported, and allows to obtain compounds of formula (I) as set forth above. Preferably, the above resin is a commercially available polystyrenic resin including, for instance, Wang resin, Trityl resin, Cl-trityl resin, Rink amide resin, Tentagel OH resin and derivatives thereof.
According to a preferred embodiment of the invention, the polystyrenic resin is a derivatized formyl polystyrenic resin which may be obtained by reacting a commercially available formyl polystyrenic resin, e.g. 4-(4-formyl-3- methoxyphenoxy)butyryl AM resin, with a suitable amino derivative under reductive conditions, for instance in the presence of sodium triacetoxyborohydride and derivatives thereof, substantially as follows:
NaBH(OAc)3 (P)-CHO + RC-NH2 *- (P)-CH2-NHRC
The reaction may be carried out in a suitable solvent such as tetrahydrofuran and in the presence of acetic acid.
The polymer- supported-amino derivatives thus obtained, particularly those, which are referable to as derivatized formyl polystyrenic resin above, are widely known in the art.
In general, amines loaded onto formylpolystyrenic resins also known as Acid Sensitive
MethoxyBenzaldehyde polystirene resins (AMEBA resin) are prepared by standard reductive amination in the presence of an excess of amine in TMOF/DCE and
NaBH(O Ac)3 or AcOH/DMF and NaCNBH3, for instance as reported in Tetrahedron Letters (1997), 38, 7151-7154; J. Am. Chem. Soc. (1998), 120, 5441; and Chem. Eur. J.
(1999), 5, 2787.
Therefore, it is a further object of the present invention a process for preparing the compounds of formula (I), and the pharmaceutically acceptable salts thereof, which process comprises: i) hydro lyzing under acid or basic conditions the compound of formula (VII) wherein
Rl represents ORc and Rc is Ci-C6 alkyl; j) reacting the resultant acid derivative with a derivatized formyl polystyrenic resin of formula (XVII):
(P)-CH2-NHR0 (XVII) wherein (P) is the resin and Rc is as defined above; k) reacting of the resultant compound of formula (XVIII):
wherein (P) and Rc are as described above, with a suitable reducing agent such as chromium (II) chloride, tetrabutylammonium hydrogen sulfide or tin (II) chloride; and 1) reacting the resultant compound of formula (XIX):
wherein (P) and Rc are as described above, as described under any one of steps from
(f.l) to (f.7); m) cleaving the resin under acidic conditions from the resultant compound of formula
(XX):
to give a compound of formula (I), wherein R is as defined above and Rl is -NHRC, wherein Rc is as defined above, optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) and/or into a pharmaceutically acceptable salt if desired.
According to step (i) of the process, the hydrolysis of a compound of formula (VII) wherein Ri is -OCH3, to give the corresponding compound of formula (VII) wherein Rl is -OH is carried out as described under step (h.l).
According to step (j) of the process, the reaction with the polystyrene resin is performed in a suitable solvent, for instance NMP, in the presence of diisopropylethylamine (DIPEA) and of a suitable condensing agent such as, for instance, l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide (EDC) or O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU).
According to step (k) of the process, the supported compound of formula (XVIII) is reduced to obtain the corresponding amino derivative; the reaction is carried out in the
presence of tin (II) chloride in dimethylformamide (DMF) at room temperature for a time ranging from 4 to 24 hours.
According to step (1), the supported compound of formula (XIX) is optionally further reacted to give to a variety of compounds functionalised in position 5 of the 3,4- dihydro-2H-pyrazino[l,2-a]indol-l-one ring, as described under any one of steps from (f.l) to (f.7).
According to step (m), the cleavage of the resin is performed under acidic conditions in the presence of suitable acids such as, for instance, hydrochloric, trifluoroacetic, methanesulfonic or p-toluensulfonic acid. Preferably the reaction is carried out using trifluoroacetic acid in dichloromethane as solvent.
Clearly, by working according to combinatorial chemistry techniques as formerly indicated, a plurality of compounds of formula (I) may be obtained. Hence, it is a further object of the present invention a library of two or more compounds of formula (I)
R is selected from the group consisting of -Ra, -CORa, -C0NR aaτR-> b , -SO2Ra and -COORa, and Rl is a group -NRcRd or -ORC, wherein Ra,Rb,Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched Ci-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl Ci-C6 alkyl, heterocyclyl or heterocyclyl Ci-C6 alkyl, aryl or aryl Ci-C6 alkyl, heteroaryl or heteroaryl Ci-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.
According to a preferred embodiment of the invention, the aforementioned library comprises the compounds of formula (I) wherein Ri is a group -NRcRd and Rc and Rd are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of Rc or Rd is a straight or branched Ci-C6 alkyl or C2-C6 alkenyl group or it is an optionally substituted aryl or arylalkyl group.
Also preferred is a library of compounds of formula (I) wherein R is either a group Ra with Ra as a hydrogen atom or a group -SO2Ra with Ra as a straight or branched Ci-C6 alkyl group or optionally substituted aryl or arylalkyl group; and Ri is as above defined. Also preferred is a library of compounds of formula (I) wherein R is a group -CORa with Ra as a straight or branched Ci-C6 alkyl, cycloalkyl or optionally substituted aryl or arylalkyl group.
Also preferred is a library of compounds of formula (I) wherein R is a group-CONRaRb with one of Ra and Rb as a hydrogen atom and the other of Ra and Rb as a straight or branched Ci-C6 alkyl, optionally substituted aryl or arylalkyl group. For a general reference to the above libraries of compounds of formula (I) see the experimental section.
From all of the above, it is clear to the skilled person that once a library of 3,4-dihydro- 2H-pyrazino[l,2-a]indol-l-one derivatives is thus prepared, for instance consisting of a few thousands of compounds of formula (I), the said library can be very advantageously used for screening towards given kinases, as formerly reported.
See, for a general reference to libraries of compounds and uses thereof as tools for screening biological activities, J. Med. Chem. 1999, 42, 2373-2382; and Bioorg. Med. Chem. Lett. 10 (2000), 223-226.
PHARMACOLOGY The inhibiting activity of putative kinase inhibitors and the potency of selected compounds is determined through a method of assay based on the use of the Kinase- GIo ® Luminescent Kinase Assay (commercially available from Promega corporation and described in Koresawa, M. and Okabe, T. (2004) High-throughput screening with quantitation of ATP consumption: A universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev. Technol. 2, 153-60).
The depletion of ATP as a result of kinase activity can be monitored in a highly sensitive manner through the use of Kinase-Glo® or Kinase-Glo® Plus Reagent, which
uses luciferin, oxygen and ATP as substrates in a reaction that produces oxyluciferin and light.
The short forms and abbreviations used herein have the following meaning:
BSA bovine serum albumine Tris 2-Amino-2-(hydroxymethyl)-l,3-propanediol
Hepes N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
DTT threo- 1 ,4-Dimercapto-2,3-butanediol
THF tetrahydrofurane
MTBE methyl tertiary butyl ether DIPEA diisopropylethylamine
PyBOP benzotriazol- 1 -yloxytris(pyrrolidino)phosphonium exafluorophosphate
TFA trifluoroacetic acid
TMOF trimethyl orto formate
DCE dichloroethane DCM dichloromethane
DMF dimethylformammide
DMSO dimethylsulfoxide
KDa kiloDalton mg milligram μg microgram ng nanogram
L liter mL milliliter μL microliter M molar mM millimolar μM micromolar nM nanomolar
Kinase reaction conditions are target (enzyme) dependent and thus undergo individual adaptations. The Kinase-Glo® Luminescent Kinase Assay can be used with virtually any kinase and substrate combination.
Also the buffer conditions may vary depending on the kinase of interest (e.g for PKA a composition of 40 mM Tris pH 7.5, 20 mM MgC12, 0.1 mg/ml BSA, in 50μl final volume is used). Typically the range of ATP titration is O.lμM to lOμM. The optimal kinase substrate results in the greatest change in luminescence when comparing kinase reaction wells with no kinase wells.
The optimal amount of kinase is determined by making two fold serial dilutions across plates using the optimal amount of ATP and optimal kinase substrate. The optimal amount of kinase to use in subsequent compound screens and IC50 determinations is the amount required for luminescence to be within the linear range of the kinase titration curve (sigmoidal dose response). Robotized Kinase-Glo® assay
This assay was set up for the measurement of kinase activity and/or inhibition. It is homogeneous, suitable for all type of protein kinases, quick and radioactivity- free. We established the assay in 384 well-plates: the test mix consisted of: 1) 3x Enzyme mix (done in Kinase Buffer 3X), 5 μl/well
2) 3x substrate and ATP mix (done in ddH2O), 5 μl/well
3) 3x compound of formula (I) (diluted into ddH2O - 3% DMSO) - 5 μl/well)
As an outcome, the percentage of inhibition at 10 μM was evaluated for each compound tested: see below for compound dilution and assay scheme. Each enzyme had its own buffer constitution, substrate type and concentration. Incubation time instead was 90 min for all targets.
Test compounds were received as a 1 mM solution in 100% DMSO into 96 well plates. The plates were diluted to 30 μM in ddH2O, 3% DMSO; 4 plates are reorganized in 384 well plate by dispensing 5 μl of each 96wp into the four quadrants of a 384wp. In well P23 and P24 the internal standard inhibitor staurosporine was added. Assay scheme
Test plates were first added with 5 μl of the compound dilution (30 μM, corresponding to 3X dilution) and then loaded onto a robotized station together with one reservoir for the Enzyme mix (3X) and one for the ATP mix (3X), specific for each target under study.
To start the assay, the robot aspirated 5 μl of ATP/Substrate mix, made an air gap inside the tips (5 μl) and aspirated 5 μl of Enzyme mix. The subsequent dispensation into the test plates allowed the kinase reaction to start after 3 cycles of mixing, done by the robot
itself by up and down pipetting. At this point, the correct concentration was restored for all reagents.
The robot incubated the plates for 90 minutes at room temperature, and then stopped the reaction by pipetting 15 μl of Kinase-Glo® reagent into the reaction mix. Three cycles of mixing were done immediately after the addition of the reagent.
The principle of the Kinase-Glo® technique is the presence in the reagent mixture of oxygen, luciferin and luciferase enzyme: in the presence of ATP, remaining from the kinase reaction, oxi-luciferin is produced with the emission of light, directly dependent on the amount of ATP. For optimal performances of this technique, the kinase reaction should utilize at least 15-20 % of the available ATP.
After another 60 minutes of incubation to stabilize the luminescent signal, the plates were read on a ViewLux® instrument. Data were analyzed using the software package
Assay Explorer® that provided percent inhibition data.
As example herein are reported the assay conditions used for testing the compounds of formula (I) against ALKtide YFF APCo kinase;
ATP concentration: 1 μM
Enzyme concentration: 100 nM
Reaction buffer: Hepes 50 mM pH 7.5, MgC12 5 mM, MnC12 1 mM, DTT 1 mM,
NaOVO3 3 uM, 0.2 mg/ml BSA Assay procedure: add 5 ul compound of formula (I) (3x), add 5 μl ATP/S mix(3x) in buffer Ix ; add 5 μl enzyme in buffer 2x+3X BSA; for the blank, add 5 μl buffer2x+3x
BSA without enzyme. After 90 minutes of incubation, add 15 μl/well of Kinase-Glo reagent. After 60-90 minutes of incubation to stabilize the luminescent signal, the plates are read on a ViuwLux instrument. Some representative compounds of the invention of formula (I), such as compound
A23-M-B63, A23-M-B55 and A20-M-B14 (for the meanings of the codes, see the
Examples section), at a dosage of 10 μM have been found to have a % inhibition > 25% when tested in the method described above.
So far, the novel compounds of the invention are unexpectedly endowed with a kinase inhibitory activity against a selected panel of kinases, and are thus particularly advantageous, in therapy, against proliferative disorders associated with an altered kinase activity.
The compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti- angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range. Compounds of formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.
The compounds of formula (I) of the present invention, suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route. For example, a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.
The present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent. The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form. For example, the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium
stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. These pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes. The liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions. As an example, the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.
The suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.
The solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.
The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin. With the aim of better illustrating the present invention, without posing any limitation to it, the following examples are now given.
Experimental section General Methods
Flash Chromatography was performed on silica gel (Merck grade 9395, 60A). The high- pressure liquid chromatography retention times (HPLC: r.t. values) were determined by: HPLC Method IA and IB:
A Waters Alliance LC mod. 2795 equipped with a variable UV detector mod 2487, a Chemiluminescence Nitrogen detector (CLND, Antek 8060) and a Waters ZQ2000 mass detector (ESI interface) was used in this application. The total flow was splitted
and distributed to the three detectors at a fixed ratio (64:15:21 UV:MS:CLND). The liquid chromatograph was equipped with a 30 x 3.0 mm LD. column (Waters xBridge C18, 3.5 um particles), thermostated at 50 0C. Two mobile phases were used: phase A was 0.05% w/v formic acid (1 mL/L of 50% formic acid Fluka 09676 in highly purified water) and phase B was 70/25/5 (v/v/v) MeOH/iPrOH/H2O containing 0.035% w/v of formic acid (700 uL/L of 50% formic acid Fluka 09676).
A 5 μL volume of 1 mM nominal sample solution in DMSO was injected (sequential, partial loop mode with no air gaps) and a generic reversed phase gradient analysis was carried out at 0.8 mL/min into either a fast variant (method IA) or a slower one (method IB), as indicated in the following table:
The UV detector was operated at 220 nm, 5 Hz sampling rate. The MS device was operated at 3.2 kV capillary voltage, 30 V cone, 2 V extractor, 0.5 V RF lens, 400 L/hr desolvation flow, 100 L/hr cone flow, 100 0C source temperature, 150 0C desolvation temperature, ESI(+) full scan 120-1200 amu acquisition, at 1.7 Hz sampling rate. The
CLND detector was operated at 1050 0C furnace temp, 280 mL/min inlet oxygen flow,
80 mL/min inlet argon, 25 mL/min make-up argon, 30 mL/min ozone, 28 torr vacuum,
750 V PMT voltage, PMT chamber at +10 0C, sensitivity high, select 5, 4 Hz sampling rate.
HPLC Method 2:
Instrumentation: Waters 2790 HPLC system equipped with a 996 Waters PDA detector and Micromass mod. ZQ 2000 single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source.
Chromatographic condition: Waters X Terra RP 18 (4,6 x 50 mm, 3.5 μm) column;
Mobile phase A was ammonium acetate 5 mM buffer (pH 5.2 with acetic acid)/acetonitrile 95:5, and Mobile phase B was H2θ/acetonitrile (5:95). Gradient from
10 to 90% B in 8 minutes, hold 100% B for 2 minutes. PDA channels extracted at 220 nm and 254 nm. Flow rate 1 ml/min. Injection volume 10 μl. Full scan, mass range from
100 to 800 amu. Capillary voltage was 3.5kV; source temp, was 1200C; cone was 14 V.
Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass is given as m/z ratio.
When necessary, the compounds have been purified by preparative HPLC on a Waters
X-Bridge Prep Shield RP18 (19 x l00 mm, 5μm) column or a Phenomenex Gemini Cl 8
(21.2 x 250 mm, lOμm) column, using a Waters FractionLynx Autopurification System equipped with a 996 Waters PDA detector and a Micromass mod. ZQ single quadrupole mass spectrometer, electron spray ionization, positive mode. Mobile phase A was water
0.05% NH3/acetonitrile 95:5, and Mobile phase B was acetonitrile. Gradient from 10 to
90% B in 8 min or 15 min. Flow rate 20 ml/min.
1H-NMR spectrometry was performed on a Bruker AVANCE 400MHz single bay instrument with gradients. It is equipped with a QNP probe (interchangeable 4 nuclei probe - 1H, 13 C, 19F and 31P) (NMR method 1) or on a Mercury VX 400 operating at
400.45 MHz equipped with a 5 mm double resonance probe [IH (15N-31P) ID PFG
Varian] (NMR method 2).
The compounds of formula (I), having an asymmetric carbon atom and obtained as racemic mixture, were resolved by HPLC separation on chiral columns. In particular, for example, preparative columns CHIRALPACK® AD, CHIRALPACK® AS,
CHIRALCELL® OJ can be used.
As formerly indicated, several compounds of formula (I) of the invention have been synthesized in parallel, according to combinatorial chemistry techniques.
In this respect, some compounds thus prepared have been conveniently and unambiguously identified, as per the coding system of tables III, VI, V and VI together with HPLC retention time (methods 1 and 2) and mass.
Each code, which identifies a single specific compound of formula (I), consists of three units A-M-B.
A represents any substituent Ri- [see formula (I)] and is attached to the rest of the 3,4- dihydro-2H-pyrazino[l,2-a]indol-l-one moiety through the carbon atom of the carbonyl group so as to get 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one derivatives; each A radical (substituent) is represented in the following table I.
B represents any substituent R- [see formula (I)] and is attached to the rest of the 3,4- dihydro-2H-pyrazino[l,2-a]indol-l-one moiety through the nitrogen atom of the NH group so as to get 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one derivatives being substituted in position 8; each B radical (substituent) is represented in the following table II.
M refers to the central core of the divalent 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one moiety being substituted at the carbonyl group by groups A and in position 8 (through the NH group) by groups B, substantially as follows:
M
B
For ease of reference, each A or B groups of tables I and II has been identified with the proper chemical formula also indicating the point of attachment with the rest of the molecule M.
Just as an example, the compound A2-M-B2 of table III (entry 1) represents an 3,4- dihydro-2H-pyrazino[l,2-a]indol-l-one M being substituted in position 8 by the group B2 (through the NH group), and by the group A2 through the CO group; likewise, the compound A4-M-09 of table IV (entry 780) represents an 3,4-dihydro-2H-pyrazino[l,2- a]indol-l-one M being substituted in position by the group B9 (through the NH group), and by the group A4 through the CO group, as follows:
A2-M-B2 A4-M-B9
Table I - A groups
Table II - B groups
LiOHH2O (1.06 g, 46.2 mmol, 2.1 eq.) was added to a suspension of 5-nitro-lH-indole- 2-carboxylic acid ethyl ester (II) (5.15 g, 22 mmol, 1 eq.) in THF/MeOH/H2O 1 :1 :2 (180 ml). The final suspension turned to dark yellow and was stirred at 25°C. After 30 min the solubilization was complete and total conversion was achieved after 6 hours. The reaction mixture was cooled to 00C and quenched with HCl 2N until the solution reached pH 5. Organic volatiles were removed under reduced pressure and the white precipitate was filtered and dried to give the compound of formula (III). Yield = 4.53 g (quantitative). Same procedure on 50 g scale afforded 42.2 g of the compound of formula (III) (96% yield).
LCMS (HPLC Method 2): m/z 205 [M-H]" @ r.t. 2.58 min . 1H NMR (400 MHz, DMSO- d6) δ ppm 2.59 (dd, J=15.91, 5.67 Hz, 1 H) 2.82 (dd, J=15.97, 8.29 Hz, 1 H) 3.58 (dd, J=12.86, 5.67 Hz, 1 H) 3.89 (dd, J=13.35, 4.08 Hz, 1 H) 5.17 - 5.23 (m, 1 H) 7.36 (s, 1 H) 7.80 (d, J=9.15 Hz, 1 H) 8.15 (dd, J=9.15, 2.32 Hz, 1 H) 8.27 (d, J=5.12 Hz, 1 H) 8.72 (d, J=2.32 Hz, 1 H) 12.58 (br. s., 1 H).
Preparation of 5-nitro-lH-indole-2-carboxylic acid (2,2-dimethoxy-ethyl)-amide (IV)
Thionyl chloride (8 ml, 110 mmol, 5 eq.) was added to a suspension of the compound of formula (III) (4.53 g, 22 mmol, 1 eq.) in dry dioxane (50 ml). The final suspension was refluxed in dry atmosphere (CaC12 valve) for 2 h, and the reaction turned to a light brown solution while proceeding. The reaction was cooled to 25°C and organic volatiles were removed under reduced pressure, then dry toluene (25 ml) was added and removed under vacuum, this operation was repeated twice. The brown residue (22 mmol, 1 eq.) was added portion wise to a cooled solution at 0 0C of NaHCO3 (3.7 g, 43.95 mmol, 2 eq.) and 2,2-dimethoxy-ethylamine (2.39 ml, 21.97 mmol, 1 eq.) in dioxane/water 4:1 (100 ml), the suspension was stirred for 2 hours at rt. Organic volatiles were removed under reduced pressure and the yellow precipitate was filtered and dried to give 5-nitro-lH- indole-2-carboxylic acid (2,2-dimethoxy-ethyl)-amide (IV). Yield = 5.80 g (90%). Same procedure on 42.2 g scale afforded 52.75 g of a compound of formula (IV)(82% yield).
LCMS (HPLC Method 2): m/z 294 [M+H]+ @ r.t. 4.46 min . 1H NMR (400 MHz,
DMSO-de) δ ppm 3.31 (s, 6 H) 3.40 (t, J=5.73 Hz, 2 H) 4.53 (t, J=5.49 Hz, 1 H) 7.43 (d,
J=I.46 Hz, 1 H) 7.57 (d, J=9.02 Hz, 1 H) 8.07 (dd, J=9.02, 2.32 Hz, 1 H) 8.70 (d, J=2.32
Hz, 1 H) 8.80 (t, J=6.04 Hz, 1 H) 12.30 (s, 1 H).
Preparation of 4-hydroxy-8-nitro-3,4-dihydro-2H-pyrazino[l,2-a]indol-l-one (V)
HCl 2N (13.75 ml, 27.5 mmol, 2.5 eq.) was added to a solution of the compound of formula (IV) (3 g, 11 mmol, 1 eq.) in acetone (200 ml), the final solution was stirred at
25°C for 48h. The solution was dried under reduced pressure affording the compound of formula (V) as yellow solid that was used in the subsequent step without further purification. Same procedure on 30 g scale proceeded smoothly. Typical yield: 97%.
Warning: on higher scale a careful drying step until constant weight is mandatory in order to avoid that residual HCl interferes in the following step.
LCMS (HPLC Method 2): m/z 246 [M-H]" @ r.t. 3.1 min (broad peak).
Preparation of (8-nitro-l-oxo-l,2,3,4-tetrahydro-pyrazino[l,2-a]indol-4-yl)-acetic acid methyl ester (VII)
LiOH^H2O (509 mg, 12.14 mmol, 1.5 eq.) was added to a solution of trimethyl phosphono acetate (VI) (1.28 ml, 8.90 mmol, 1.2 eq.), to the compound of formula (V)
(2.0 g, 8.09 mmol, 1 eq.) and water (4.4 ml, 240 mmol, 30 eq.) in THF (100 ml) and the solution was stirred at 25°C for 4 hours, then organic volatiles were removed under reduced pressure and the crude residue was used in the next step without further purification, after addition of 100 ml of water.
On higher scale (110 mol) the reaction was worse (low conversion) for the mentioned above residue of HCl.
LCMS (HPLC Method 2): m/z 304 [M+H]+ @ r.t. 3.96 min. 1H NMR (on isolated product) (400 MHz, DMSO-d6) δ ppm 2.68 (dd, J= 15.61, 6.22 Hz, 1 H) 2.92 (dd,
J=15.49, 7.44 Hz, 1 H) 3.51 (s, 3 H) 3.58 (ddd, J=13.29, 5.37, 1.10 Hz, 1 H) 3.90 (dd,
J=13.41, 4.15 Hz, 1 H) 5.25 (dt, J=6.83, 3.66 Hz, 1 H) 7.36 (s, 1 H) 7.75 (d, J=9.15 Hz, 1
H) 8.17 (dd, J=9.27, 2.32 Hz, 1 H) 8.28 (d, J=5.00 Hz, 1 H) 8.72 (d, J=2.20 Hz, 1 H).
Preparation of (8-nitro-l-oxo-l,2,3,4-tetrahydro-pyrazino[l,2-a]indol-4-yl)-acetic acid (VII)
LiOH^H2O (408 mg, 9.72 mmol, 1.2 eq.) was added to aqueous solution of the crude of example 4 and the resultant suspension was stirred at 25°C for 4 hours. The brown suspension was filtered. The dark brown mother solution was quenched with HCl 2N until pH 5 was reached (yellow precipitate), organic volatiles were removed under reduced pressure and the yellow precipitate was filtered. The crude material was stirred with acetone (20 ml/g of crude) for 12 hours then the undissolved material was filtered and dried under reduced pressure (light yellow solid). Yields: 1.2 g of the acid derivative of formula (VII) (50% over two steps) 89% UV purity @254nm.
Same procedure on higher scale afforded the compound of formula III with average yields of 35% over two steps and 90% UV purity @254nm, the main impurity is the starting material of example 4.
LCMS (HPLC Method 2): m/z 288 [M-H]" @ r.t. 2.62 min. 1H NMR (400 MHz, DMSO- d6) δ ppm 2.59 (dd, J=15.91, 5.67 Hz, 1 H) 2.82 (dd, J=15.97, 8.29 Hz, 1 H) 3.58 (dd, J=12.86, 5.67 Hz, 1 H) 3.89 (dd, J=13.35, 4.08 Hz, 1 H) 5.17 - 5.23 (m, 1 H) 7.36 (s, 1 H) 7.80 (d, J=9.15 Hz, 1 H) 8.15 (dd, J=9.15, 2.32 Hz, 1 H) 8.27 (d, J=5.12 Hz, 1 H) 8.72 (d, J=2.32 Hz, 1 H) 12.58 (br. s., 1 H).
General procedure: loading of Allylamine (corresponding to fragment A7 of Table I) onto Acid Sensitive Methoxy Benzaldehyde polystyrene resin (AMEBA II resin). 4-(4-formyl-3-methoxyphenoxy)butyryl amino methyl resin (copolystyrene-l%DVB) (6.0 g, 5.88 mmol, 0.98 mmol/g, 1 eq.) was suspended in dry THF (60 ml) and allylamine (29.4 mmol, 5 eq.) was added. The resultant suspension was shaken at 25°C for 2 h. Then acetic acid (1.68 ml, 29.4 mmol, 5 eq.) and NaBH(AcO)3 (3.12 g, 14.7 mmol, 3 eq.) were added and the final suspension was shaken for 16 h at 25 0C. The resin was rinsed with THF (2 cycles), MeOH (2 cycles), DCM (2 cycles), MeOH (2 cycles), DMF (2 cycles) and DCM (3 cycles) then dried in nitrogen flux.
Loading of the 3,4-dihydro-2h-pyrazino[l,2-a]indol-l-one scaffold onto the resin prepared above
A solution of the acid derivative of formula (VII) (57 mg, 0.2 mmol, 2 eq), DIPEA (0.068 ml, 0.39 mmol, 4 eq.), PyBOP (102.75 mg, 0.2 mmol, 2 eq.) in dry DMA (2.0 ml) was stirred for 30 min then was added to resin of example 6 (0.1 mmol, 1 eq.) and the final suspension was shaken for 2Oh at 250C. The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then air dried. Reduction of the nitro group
The resin of formula (XVIII) (0.1 mmol, 1 eq.) was suspended in a 2M solution of SnCl2*2H2θ in DMF (1.5 ml). The final compound of formula (XIX) in suspension was shaken for 48 hours at 25°C. The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then dried in nitrogen flux. The above resin bound 3,4-dihydro-2h-pyrazino[l,2-a]indol-l-one was
further reacted according to the alternative steps below so as to get carboxamido, sulfonamido, ureido and amino derivatives.
Example 1 Preparation of A28-M-B1
A carboxylic acid of formula (VIII), wherein Ra corresponds to the fragment Bl of table II, (0.3 mmol, 3 eq.), was added to a the resin of example 8 wherein Rc corresponds to the fragment A28 of table I, in solution of DIPEA (68.5 μl, 0.4 mmol, 4 eq.) and PyBOP (156 mg, 0.3 mmol, 3 eq.) in dry DMF (2.5 ml) and the solution was stirred for 30 min then was added to the resin of example 8 (0.1 mmol, 1 eq.) and shaken at 25°C in a reactor (Quest 210™ or Miniblocks™). The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then air dried. The Resin (0.1 mmol, 1 eq.) was suspended in a solution of TFA/DCM 1 :1 (2 ml) and shaken for 2 h at 25°C. The solution phase was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected were dried under reduced pressure affording compound A28-M-B1 (see entry 754 of table III below).
LCMS (HPLC Method IA): m/z 377 [M+H]+ @ r.t. 2.41 min. 1H NMR (400 MHz, DMSO-J6) δ ppm 9.62 (s, IH), 8.07 (s, IH), 8.03 (d, J = 4.9 Hz, IH), 7.92 (t, J = 5.6 Hz, IH), 7.36 - 7.47 (m, 2H), 7.00 (s, IH), 4.85 - 5.14 (m, IH), 3.83 (dd, J = 13.2, 4.3 Hz, IH), 3.48 (dd, J = 12.8, 5.6 Hz, IH), 3.09 (s, 2H), 2.85 - 3.03 (m, 2H), 2.31 (s, 6H), 2.20 (br. s., 8H), 1.27 - 1.51 (m, 2H).
Following the procedure described in example 9 and by using any proper reactant as per the process of the invention that is, by supporting any suitable amine onto the resin, by acylating the amino function in position 8 of the 3,4-dihydro-2H-pyrazino[l,2-a]indol-l-
one moiety with any suitable carboxylic acid derivative and by finally carrying out resin cleavage, the following compounds of table III were also prepared. Table III
Example 2
Preparation of A2-M-B9
A sulfonyl chloride of formula (X), wherein Ra corresponds to fragment B9 of table II, (0.12 mmol, 1.2 eq.) was added to a suspension of the resin of example 8 wherein Rc corresponds to the fragment A2 of table I (0.1 mmol, 1 eq.) in dry DCM (2,5 ml) and N- methyl morpholine (22.0 μl, 0.2 mmol, 2 eq.). The final suspension was shaken overnight at 25°C in a reactor (Quest 210™ or Minib locks™). The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml),
MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then air dried. The Resin (0.1 mmol, 1 eq.) was suspended in a solution of TFA/DCM 1 :1 (2 ml) and shaken for 2 h at 250C. The solution phase was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected were dried under reduced pressure affording compound A2-M-B9 (see entry 774 of table IV below). LCMS LCMS (HPLC Method IB): m/z 519 [M+H]+ @ r.t. 3.2 min. 1H NMR (400 MHz, DMSO-J6) δ ppm 8.03 (d, J = 5.0 Hz, IH), 7.86 (t, J = 5.4 Hz, IH), 7.66 - 7.72 (m, 2H), 7.56 - 7.61 (m, 2H), 7.37 (d, J = 8.9 Hz, IH), 7.33 (d, J = 1.8 Hz, IH), 6.99 (dd, J = 9.0, 2.0 Hz, IH), 6.96 (s, IH), 4.91 - 5.00 (m, IH), 3.77 (dd, J = 13.0, 4.5 Hz, IH), 3.42 - 3.49 (m, IH), 2.85 - 2.94 (m, 2H), 2.38 - 2.58 (m, 2H), 2.13 (br. s., 8H), 1.29 - 1.40 (m, 2H). Following the procedure described in example 10 and by using any proper reactant as per the process of the invention that is, by supporting any suitable amine onto the resin, by sulfonylation the amino function in position 8 of the 3,4-dihydro-2H-pyrazino[l,2- a]indol-l-one moiety with any suitable sulfonyl chloride derivative and by finally carrying out resin cleavage, the following compounds of table IV were also prepared. Table IV
Example 3
Preparation of A7-M-B6
An isocyanate of formula (IX), wherein Ra corresponds to fragment B6 of table II, (0.3 mmol, 3 eq.) was added to a suspension of the resin of example 8 wherein Rc corresponds to the fragment A7 of table I (0.1 mmol, 1 eq.) in dry DCM (2,5 ml) and DIPEA (17.1 μl, 0.1 mmol, 1 eq.). The final suspension was shaken overnight at 25°C in a reactor (Quest 210™ or Minib locks™). The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then air dried. The Resin (0.1 mmol, 1 eq.) was suspended in a solution of TFA/DCM 1 :1 (2 ml) and shaken for 2 h at 25°C. The solution phase was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected were dried under reduced pressure affording compound A7-M-B6 (see entry 937 of table V below).
LCMS (HPLC Method IB): m/z 448 [M+H]+ @ r.t. 4.3 min. 1H NMR (400 MHz, DMSO-J6) δ ppm 8.51 (s, IH), 8.46 (s, IH), 8.11 (t, J = 5.6 Hz, IH), 8.00 (d, J = 5.0 Hz, IH), 7.83 (d, J = 1.7 Hz, IH), 7.43 (d, J = 8.9 Hz, IH), 7.34 - 7.39 (m, 2H), 7.24 (dd, J = 9.0, 2.0 Hz, IH), 6.97 (s, IH), 6.84 - 6.89 (m, 2H), 5.59 - 5.71 (m, IH), 4.95 - 5.04 (m, 3H), 3.83 (dd, J = 12.9, 4.0 Hz, IH), 3.72 (s, 3H), 3.60 - 3.65 (m, 2H), 3.49 (dd, J = 13.4, 5.2 Hz, IH), 2.57 - 2.64 (m, IH), 2.46 - 2.53 (m, IH).
Following the procedure described in example 11 and by using any proper reactant as per the process of the invention, that is by supporting any suitable amine onto the resin, by preparing the carbamate derivative in position 8 of the 3,4-dihydro-2H-pyrazino[l,2- a]indol-l-one moiety with any suitable isocyanate derivative and by finally carrying out resin cleavage, the following compounds of table V were also prepared.
TableV
Example 4
Preparation of A14-M-B76
An aldehyde of formula (XIII, wherein Ra corresponds to the fragment B76 of table II, (1.0 mmol, 10 eq.) was added to a suspension of the resin of example 8 wherein Rc corresponds to the fragment Al 4 of table I (0.1 mmol, 1 eq.) in a dry mixture CH(OCH3)3/DMF/MeOH 9:1 :2 (2 ml) and acetic acid (20 μl). The final suspension was shaken overnight at 25°C in a reactor (Quest 210™ or Miniblocks™). The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml). The Resin (0.1 mmol, 1 eq.) was suspended in THF, NaCNBH3 (314 mg, 5.0 mmol, 50 eq.) was added and the final suspension was shaken for 16 h at 25 0C. The resin was washed sequentially with DMF (1 ml), DCM (1 ml), DMF (1 ml), DCM (1 ml), MeOH (1 ml), water (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), DCM (1 ml), MeOH (1 ml), MTBE (1 ml, 2 cycles) and then air dried. The Resin (0.1 mmol, 1 eq.) was suspended in
a solution of TFA/DCM 1 :1 (2 ml) and shaken for 2 h at 25°C. The solution phase was collected and the resin was rinsed with DCM (collected as well), and a second cycle was performed. The final washing was performed with MeOH. All the collected were dried under reduced pressure affording compound A14-M-B76 (see entry 1039 of table VI below).
LCMS (HPLC Method 2): m/z 517 [M+H]+ @ r.t. 5.91 min . 1H NMR (400 MHz, DMSO-J6) δ ppm 8.40 (t, J=5.7 Hz, 2 H), 7.87 - 8.04 (m, 2 H), 7.27 - 7.33 (m, 2 H), 7.01 (dd, J=7.6, 1.6 Hz, 3 H), 4.88 - 5.08 (m, 2 H), 4.38 (s, 3 H), 4.06 - 4.26 ppm (m, 4 H). Following the procedure described in example 12 and by using any proper reactant as per the process of the invention, that is by supporting any suitable amine onto the resin, by preparing the amino derivative in position 8 of the 3,4-dihydro-2H-pyrazino[l,2-a]indol- 1-one moiety with any suitable aldehyde derivative and by finally carrying out resin cleavage, the following compounds of table VI were also prepared. TableVI
Claims
I) A compound of formula (I)
R is selected from the group consisting of -Ra, -CORa, -CONR > aaτR-> bD, -SO2Ra and
-COORa, and
Rl is a group -NRcRd or -ORC, wherein Ra,Rb,Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched Ci-C6 alkyl, C2-
C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl Ci-C6 alkyl, heterocyclyl or heterocyclyl Ci-C6 alkyl, aryl or aryl Ci-C6 alkyl, heteroaryl or heteroaryl Ci-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.
2) A compound of formula (I) according to claim 1 wherein:
Rl is a group -NRcRd and Rc and Rd are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of Rc or Rd is a straight or branched Ci-C6 alkyl or C2-C6 alkenyl group or it is an optionally substituted aryl or arylalkyl group.
3) A compound of formula (I) according to claims 1 or 2 wherein:
R is a group Ra wherein Ra is hydrogen, or is a group -SO2Ra wherein Ra is straight or branched Ci-C6 alkyl or optionally substituted aryl or arylalkyl.
4) A compound of formula (I) according to claims 1 or 2 wherein:
R is a group -CORa wherein Ra is a straight or branched Ci-C6 alkyl, cycloalkyl or optionally substituted aryl or arylalkyl group.
5) A compound of formula (I) according to claims 1 or 2 wherein:
R is a group -C0NRaRb wherein one of Ra and Rb are hydrogen and the other is straight or branched Ci-C6 alkyl, optionally substituted aryl or arylalkyl group.
6) A compound of formula (I) according to claims 1 to 5 wherein any of Ra, Rb, Rc and Rd is independently halogen, nitro, optionally substituted oxo groups (=0), carboxy, cyano, Ci-C6 alkyl, polyfluorinated alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, amino groups, carbonylamino groups or hydroxy groups.
7) A compound of formula (I) according to any one of claims 1 to 6 wherein Rl is a fragment denoted by any of codes A1-A28 and R is a fragment denoted by any of codes B1-B76
8) A process for preparing a compound of formula (I) as defined in claim 1 characterized in that the process comprises: f) reacting a compound of formula (I) :
wherein R is hydrogen and Rl is -ORC and Rc is Ci-C6 alkyl, according to any one of the alternative steps: f.1) with an acid or an acyl halide of formula (VIII):
RaCOZ (VIII) wherein Ra is as defined in claim 1 and Z is a halogen or a group -OH, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.2) with an isocyanate of formula (IX):
RaNC0 (IX) wherein Ra is as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.3) with a sulphonyl halide of formula (X):
RaSO2Z' (X) wherein Ra is as defined above and Z' is a halogen, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.4) with a halogen carbonate of formula (XI):
RaOCOZ' (XI) wherein Ra and Z' are as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above; or f.5) with an amine of formula (XII):
HNRaRb (XII) wherein Ra and Rb are as defined above, in presence of a suitable chloro formate, to give a compound of formula (I):
wherein Rl is -ORC and
as defined above; or (f.6) with a suitable aldehyde or ketone derivative of formula (XIII):
Ra-CO-Ra (XIII) wherein each of Ra, the same or different, are as defined above, to give a compound of formula (I):
(f.7) with an halide of formula (XIV):
Ra-Z' (XIV) wherein Ra and Z' are as defined above, to give a compound of formula (I):
wherein Rl is -ORC and Rc is Ci-C6 alkyl and Ra are as defined above;
optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by replacing the group -ORC with a different group among those represented by Rl as defined in claim 1 , and/or into a pharmaceutically acceptable salt if desired. 9) A process according to claim 8, characterized in that the compound of formula (I) wherein R is hydrogen and Rl is -ORC and Rc is Ci-C6 alkyl, is prepared according to the following steps: a) hydro lysing under basic or acidic conditions the compound of formula (II):
(H) b) reacting the resultant compound of formula (III) or a salt thereof:
with 2,2-dimethoxy-ethylamine, after activation of the carboxyl group; c) deprotecting under acidic conditions the resultant compound of formula (IV):
with a phosphonate of formula (VI):
wherein AIk is Ci-C6 alkyl and Rc is Ci-C6 alkyl; optionally converting the resultant compound of formula (VII):
wherein Rl represents ORcand Rcis Ci-C6 alkyl, into another compound of formula (VII) by replacing the -ORC group with a different group among those represented by Rl as defined in claim 1 ; e) reducing said compound of formula (VII) to give a compound of formula (I) or a salt thereof:
wherein Rl is as defined above; optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) by derivatising the amino moiety, and/or by replacing the group -ORC with a different group among those represented by Rl as defined in claim 1, and/or into a pharmaceutically acceptable salt if desired.
10) A process according to claim 8, characterized in that the optional conversion of a compound of formula (I) into another compound of formula (I), is carried out by one or more of the following reactions: g.l) acid or basic hydrolysis of a compound of formula (I) wherein Rl is -ORC and Rc is Ci-C6 alkyl, to give the corresponding compound of formula (I) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt; g.2) transesterification of a compound of formula (I) wherein Rl is -ORC and Rc is C1- C6 alkyl, by reactions with a compound of formula (XV):
RC-OH (XV) to give the corresponding compound of formula (I) wherein Rl is -ORC and Rc is a different Ci-C6 alkyl; g.3) aminolysis of a compound of formula (I) wherein Ri is -ORC and Rc is Ci-C6 alkyl, by reaction with a compound of formula (XVI):
HNRcRd (XVI) to give the corresponding compound of formula (I) wherein Rl is -NRcRd ; g.4) esterifϊcation of a compound of formula (I) wherein Rl is a group -OH or its corresponding salt, by reactions with a compound of formula (XV) as defined above, to give the corresponding compound of formula (I) wherein Rl is -ORC ; g.5) amidation of a compound of formula (I) wherein Rl is a group -OH or its corresponding salt, by reaction with a compound of formula (XVI) as defined above, to give the corresponding compound of formula (I) wherein Rl is -NRcRd .
11) A process according to claim 8 and 9, characterized in that the compound of formula (VII):
wherein Rl is as defined in claim 1, is converted into another compound of formula (VII), said conversion is carried out by one or more of the following reactions:
h.l) acid or basic hydrolysis of a compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl, to give a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt; h.2) transesterification of a compound of formula (VII) wherein Rl is -ORC and Rc is
Ci-C6 alkyl, by reaction with a compound of formula (XV) as defined in claim 10, to give a compound of formula (VII) wherein Rl is -ORC and Rcis a different Ci-C6 alkyl; h.3) amidation of a compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl, by reaction with a compound of formula (XVI) as defined in claim 10, to give a compound of formula (VII) wherein Rl is -NRcRd ; h.4) esterification of a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, or the corresponding salt, by reaction with a compound of formula (XV) as defined above, to give a compound of formula (VII) wherein Rl is -ORC and Rc is different from hydrogen; h.5) amidation of a compound of formula (VII) wherein Rl is -ORC and Rc is hydrogen, by reaction with a compound of formula (XVI) as defined above, to give a compound of formula (VII) wherein Rl is -NRcRd .
12) A process for preparing a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises: i) hydro lyzing under acid or basic conditions the compound of formula (VII) wherein Rl is -ORC and Rc is Ci-C6 alkyl; j) reacting the resultant acid derivative with a derivatized formyl polystyrenic resin of formula (XVII):
(P)-CH2-NHR0 (XVII) wherein (P) is the resin and Rc is as defined in claim 1 ; k) reacting of the resultant compound of formula (XVIII):
wherein (P) and Rc are as described above, with a suitable reducing agent such as chromium (II) chloride, tetrabutylammonium hydrogen sulfide or tin (II) chloride; and
1) reacting the resultant compound of formula (XIX):
wherein (P) and Rc are as described above, as described under any one of steps from (f.l) to (f.7); m) cleaving of the resin under acidic conditions from the resultant compound of formula
(XX):
to give a compound of formula (I), wherein R is as defined in claim 1 and Rl is -NHRC, wherein Rc is as defined in claim 1, optionally separating the resultant compound of formula (I) into the single isomers; converting the resultant compound of formula (I) into a different compound of formula (I) and/or into a pharmaceutically acceptable salt if desired.
R is selected from the group consisting of -Ra, -CORa, -C0NRaRb, -SO2Ra and
-COORa, and
Rl is a group -NRcRd or -ORC; wherein Ra, Rb, Rc and Rd, the same or different, are each independently hydrogen or a group optionally further substituted, selected from straight or branched Ci-C6 alkyl, C2-
C6 alkenyl or C2-C6 alkynyl, C3-C6 cycloalkyl or cycloalkyl Ci-C6 alkyl, heterocyclyl or heterocyclyl Ci-C6 alkyl, aryl or aryl Ci-C6 alkyl, heteroaryl or heteroaryl Ci-C6 alkyl or, taken together with the nitrogen atom to which they are bonded, either Ra and Rb as well as Rc and Rd may form an optionally substituted 3 to 7 membered heterocyclyl or heteroaryl, optionally containing one additional heteroatom or heteroatomic group selected from S, O, N or NH, and pharmaceutically acceptable salts thereof.
14) A library according to claim 13 wherein Ri is a group -NRcRd and Rc and Rd are both hydrogen atoms or one of them is a hydrogen atom and the remaining one of Rc or Rd is a straight or branched Ci-C6 alkyl or C2-C6 alkenyl group or it is an optionally substituted aryl or arylalkyl group.
15) A library according to claims 13 or 14 wherein R is either a group Ra with Ra as a hydrogen atom or a group -SO2Ra with Ra as a straight or branched Ci-C6 alkyl or optionally substituted aryl or arylalkyl group.
16) A library according to claims 13 or 14 wherein R is a group -CORa with Ra as a straight or branched Ci-C6 alkyl, cycloalkyl or optionally substituted aryl or arylalkyl group.
17) A library according to claims 13 or 14 wherein R is a group -C0NRaRb with one of Ra and Rb as a hydrogen atom and the other of Ra and Rb as a straight or branched Ci-C6 alkyl, optionally substituted aryl or arylalkyl group.
18) A library according to claim 12 wherein the compound has the formula:
M
B
wherein fragments A and B are as defined in claim 7, and wherein the compound is one of those listed hereinbelow:
19) A method for treating a disease caused by and/or associated with a dysregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1.
20) The method according to claim 19 wherein the disease caused by and/or associated with a dysregulated protein kinase activity is selected from the group consisting cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders.
21) The method according to claim 20 wherein the cancer is selected from the group consisting of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukaemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; other tumors, including mesothelioma, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.
22) The method according to claim 20 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
23) The method according to claim 19 which provides tumour angiogenesis and metastasis inhibition, as well as treatment of organ transplant rejection and host versus graft disease.
24) The method according to claim 19 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.
25) The method according to claim 19 wherein the mammal in need thereof is a human.
26) An in vitro method for inhibiting protein kinase activity which comprises contacting the kinase with an effective amount of a compound of formula (I) as defined in claim 1.
27) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 and, at least, one pharmaceutically acceptable excipient, carrier and/or diluent.
28) A pharmaceutical composition according to claim 27 further comprising one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
29) A product or kit comprising a compound of formula (I) as defined in claim 1 or a pharmaceutical composition thereof as defined in claim 27, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
30) A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1 , for use as a medicament.
31) A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1 , for use in a method for treating diseases caused by and/or associated with an altered protein kinase activity.
32) Use of a compound of formula (I) or of a pharmaceutically acceptable salt thereof, as defined in claim 1 , in the manufacture of a medicament for treating diseases caused by and/or associated with an altered protein kinase activity.
33) An intermediate of formula (VII):
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/934,422 US8207165B2 (en) | 2008-03-28 | 2009-03-27 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
EP09724061.8A EP2254886B1 (en) | 2008-03-28 | 2009-03-27 | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
JP2011501241A JP5767101B2 (en) | 2008-03-28 | 2009-03-27 | 3,4-Dihydro-2H-pyrazino [1,2-A] indol-1-one derivatives active as kinase inhibitors, methods for their preparation, and pharmaceutical compositions containing them |
ES09724061.8T ES2588193T3 (en) | 2008-03-28 | 2009-03-27 | Derivatives of 3,4-dihydro-2H-pyrazino [1,2-a] indole-1-one active as kinase inhibitors, process for its preparation and pharmaceutical compositions comprising them |
US13/482,626 US8513241B2 (en) | 2008-03-28 | 2012-05-29 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08153532 | 2008-03-28 | ||
EP08153532.0 | 2008-03-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/934,422 A-371-Of-International US8207165B2 (en) | 2008-03-28 | 2009-03-27 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US13/482,626 Continuation US8513241B2 (en) | 2008-03-28 | 2012-05-29 | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009118411A2 true WO2009118411A2 (en) | 2009-10-01 |
WO2009118411A3 WO2009118411A3 (en) | 2010-03-11 |
Family
ID=40988230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/053668 WO2009118411A2 (en) | 2008-03-28 | 2009-03-27 | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Country Status (5)
Country | Link |
---|---|
US (2) | US8207165B2 (en) |
EP (1) | EP2254886B1 (en) |
JP (1) | JP5767101B2 (en) |
ES (1) | ES2588193T3 (en) |
WO (1) | WO2009118411A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013542988A (en) * | 2010-11-22 | 2013-11-28 | フェニックス・バイオテクノロジー・インコーポレイテッド | Methods of treating neurological conditions with extracts of Oleander species or Thevetia species |
US9006245B2 (en) | 2012-03-16 | 2015-04-14 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9073931B2 (en) | 2012-03-16 | 2015-07-07 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
EP2785720A4 (en) * | 2011-11-29 | 2015-11-11 | Nanjing Allgen Pharma Co Ltd | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2017176751A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2018071447A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018071454A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
WO2018170381A1 (en) | 2017-03-16 | 2018-09-20 | Andrews Steven W | Macrocyclic compounds as ros1 kinase inhibitors |
US10251889B2 (en) | 2009-07-09 | 2019-04-09 | Array BioPharm Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
WO2019075108A1 (en) | 2017-10-10 | 2019-04-18 | Metcalf Andrew T | Crystalline forms |
WO2019075114A1 (en) | 2017-10-10 | 2019-04-18 | Mark Reynolds | Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
WO2020028258A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide |
WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
WO2021134004A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
WO2022055963A1 (en) | 2020-09-10 | 2022-03-17 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
WO2022197898A1 (en) | 2021-03-18 | 2022-09-22 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2528918B1 (en) * | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
KR102025848B1 (en) | 2010-12-01 | 2019-11-05 | 앨더바이오 홀딩스 엘엘씨 | Anti-ngf compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
WO2013050446A1 (en) * | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044753A1 (en) * | 1999-01-29 | 2000-08-03 | Vernalis Research Limited | Pirazino(aza)indole derivatives |
WO2002010169A1 (en) * | 2000-07-31 | 2002-02-07 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002072584A2 (en) * | 2001-03-13 | 2002-09-19 | F. Hoffmann-La Roche Ag | Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
WO2007065820A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19802235A1 (en) * | 1998-01-22 | 1999-07-29 | Bayer Ag | New oxazolidinone derivatives useful as antibacterial agents for treating local or systemic infections in humans or animals |
IT1313593B1 (en) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | 1,2-DIIDRO-1-OXO-PIRAZINO 1,2-A INDOL DERIVATIVES. |
-
2009
- 2009-03-27 JP JP2011501241A patent/JP5767101B2/en active Active
- 2009-03-27 WO PCT/EP2009/053668 patent/WO2009118411A2/en active Application Filing
- 2009-03-27 EP EP09724061.8A patent/EP2254886B1/en active Active
- 2009-03-27 US US12/934,422 patent/US8207165B2/en active Active
- 2009-03-27 ES ES09724061.8T patent/ES2588193T3/en active Active
-
2012
- 2012-05-29 US US13/482,626 patent/US8513241B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044753A1 (en) * | 1999-01-29 | 2000-08-03 | Vernalis Research Limited | Pirazino(aza)indole derivatives |
WO2002010169A1 (en) * | 2000-07-31 | 2002-02-07 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
WO2002072584A2 (en) * | 2001-03-13 | 2002-09-19 | F. Hoffmann-La Roche Ag | Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
WO2007065820A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10758542B2 (en) | 2009-07-09 | 2020-09-01 | Array Biopharma Inc. | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10251889B2 (en) | 2009-07-09 | 2019-04-09 | Array BioPharm Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
JP2013542988A (en) * | 2010-11-22 | 2013-11-28 | フェニックス・バイオテクノロジー・インコーポレイテッド | Methods of treating neurological conditions with extracts of Oleander species or Thevetia species |
EP2785720A4 (en) * | 2011-11-29 | 2015-11-11 | Nanjing Allgen Pharma Co Ltd | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
US9416135B2 (en) | 2012-03-16 | 2016-08-16 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9814715B2 (en) | 2012-03-16 | 2017-11-14 | Vitae Pharamceuticals, Inc. | Liver X receptor modulators |
US9073931B2 (en) | 2012-03-16 | 2015-07-07 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9006245B2 (en) | 2012-03-16 | 2015-04-14 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9707232B2 (en) | 2012-03-16 | 2017-07-18 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9006244B2 (en) | 2012-03-16 | 2015-04-14 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US9388190B2 (en) | 2012-03-16 | 2016-07-12 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
US10138243B2 (en) | 2015-07-16 | 2018-11-27 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
US10174028B2 (en) | 2015-07-16 | 2019-01-08 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US10023570B2 (en) | 2015-07-16 | 2018-07-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
WO2017011776A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US10174027B2 (en) | 2015-07-16 | 2019-01-08 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10137127B2 (en) | 2016-04-04 | 2018-11-27 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10588908B2 (en) | 2016-04-04 | 2020-03-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10668072B2 (en) | 2016-04-04 | 2020-06-02 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2017176751A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
US10137124B2 (en) | 2016-10-10 | 2018-11-27 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
US10112942B2 (en) | 2016-10-10 | 2018-10-30 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US11648243B2 (en) | 2016-10-10 | 2023-05-16 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
EP4144735A1 (en) | 2016-10-10 | 2023-03-08 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US10172845B2 (en) | 2016-10-10 | 2019-01-08 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US10144734B2 (en) | 2016-10-10 | 2018-12-04 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US10441581B2 (en) | 2016-10-10 | 2019-10-15 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
WO2018071454A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US10555944B2 (en) | 2016-10-10 | 2020-02-11 | Eli Lilly And Company | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US10172851B2 (en) | 2016-10-10 | 2019-01-08 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
US10881652B2 (en) | 2016-10-10 | 2021-01-05 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
EP3753939A1 (en) | 2016-10-10 | 2020-12-23 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US10953005B1 (en) | 2016-10-10 | 2021-03-23 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
WO2018071447A1 (en) | 2016-10-10 | 2018-04-19 | Andrews Steven W | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
US11851434B2 (en) | 2017-01-18 | 2023-12-26 | Array Biopharma Inc. | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
US10966985B2 (en) | 2017-03-16 | 2021-04-06 | Array Biopharma Inc. | Macrocyclic compounds as ROS1 kinase inhibitors |
WO2018170381A1 (en) | 2017-03-16 | 2018-09-20 | Andrews Steven W | Macrocyclic compounds as ros1 kinase inhibitors |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
WO2019075108A1 (en) | 2017-10-10 | 2019-04-18 | Metcalf Andrew T | Crystalline forms |
WO2019075114A1 (en) | 2017-10-10 | 2019-04-18 | Mark Reynolds | Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2020028258A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide |
WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
WO2021134004A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
WO2022055963A1 (en) | 2020-09-10 | 2022-03-17 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
WO2022197898A1 (en) | 2021-03-18 | 2022-09-22 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
US8513241B2 (en) | 2013-08-20 |
EP2254886B1 (en) | 2016-05-25 |
EP2254886A2 (en) | 2010-12-01 |
ES2588193T3 (en) | 2016-10-31 |
JP2011515452A (en) | 2011-05-19 |
WO2009118411A3 (en) | 2010-03-11 |
JP5767101B2 (en) | 2015-08-19 |
US20120232085A1 (en) | 2012-09-13 |
US20110183971A1 (en) | 2011-07-28 |
US8207165B2 (en) | 2012-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2254886B1 (en) | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
JP5746032B2 (en) | 3,4-Dihydro-2H-pyrrolo [1,2-a] pyrazin-1-one derivatives | |
EP2528918B1 (en) | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators | |
JP2012502951A5 (en) | ||
EP1704147B1 (en) | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | |
EP1701956B1 (en) | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
EP1202734B1 (en) | 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents | |
US9701686B2 (en) | Tricyclopyrazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09724061 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009724061 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12934422 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011501241 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |